AP-188 DMT being developed as a possible treatment of ischemic stroke and for post-stroke rehabilitation

Algernon has started a clinical research program for stroke focused on AP-188 (“N,N-Dimethyltryptamine or DMT”), a known psychedelic compound that is part of the tryptamine family.

Algernon plans to be the first Company globally to pursue DMT for stroke in humans and is planning to begin a clinical trial as soon as possible in 2021.

Compound DMT
Country Canada
Visit trial

Trial Details



Trial Number

Sponsors & Collaborators

Algernon Pharmaceuticals
Algernon is a clinical stage pharmaceutical company that is developing novel psychedelic molecules (based on DMT) for the treatment of stroke-related dysfunction.

Data attribution

A large set of the trials in our database are sourced from ClinicalTrials.gov (CTG). We have modified these post to display the information in a more clear format or to correct spelling mistakes. Our database in actively updated and may show a different status (e.g. completed) if we have knowledge of this update (e.g. a published paper on the study) which isn't reflected yet on CTG. If a trial is not sourced from CTG, this is indicated on this page and you can follow the link to the alternative source of information.